 Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.
Dear Reader, In this short 3-min. video, legendary investor James Altucher reveals the name and ticker symbol of a company he believes will skyrocket as soon as June 9th… 100% FREE of charge. No tricks. No gimmicks. Free. The company he reveals here is directly tied to the hotly anticipated IPO of Elon Musk’s Starlink… Which is estimated to be worth $100 BILLION when it finally goes public. That would make it the biggest IPO in history! And right now – today… You can get a “pre-IPO” recommendation on Starlink before it goes public… From one of the most successful investors in the world – completely FREE of charge. Click here to watch the video now. It’s only 3 minutes long… And it could give you an early stake in one of the biggest profit opportunities of all time.
Click here to check it out before it’s too late. Best, Matt Insley
Publisher, Paradigm Press P.S. Starlink could go public as soon as June 9th. So for your chance at the biggest possible gains… Make sure you act on this ASAP. Click here to watch James’ urgent 3 min. video now.
Bonus News from MarketBeat Media
Aggressive Insider Buying Signals Opportunity in 3 Risky StocksBy Thomas Hughes. First Published: 6/2/2026. 
Key Points
- Insiders at HeartBeam, Sportradar, and Granite Ridge Resources are aggressively buying shares, signaling confidence despite distinct risks at each company.
- HeartBeam analysts see up to 390% upside as the med-tech firm nears commercialization of its ECG device, though cash burn and adoption hurdles remain.
- Granite Ridge's nearly 9% dividend yield attracts insider buying, but a consensus Reduce rating and dividend sustainability concerns tied to cash burn pose meaningful risks.
- Special Report: How to own the rails before SpaceX goes public
Insiders are aggressively buying stocks like HeartBeam (NASDAQ: BEAT), Sportradar Group (NYSE: SRAD), and Granite Ridge Resources (NYSE: GRNT), highlighting three very different risk/reward setups. While risks are present, the upside potential is significant. The question is whether these companies can execute their strategies, navigate headwinds, and prove their naysayers wrong. Any missteps or unexpected hurdles will be reflected in their stock prices. HeartBeam: A Heartbeat Away From Higher Prices
HeartBeam is an emerging med-tech startup on the cusp of commercializing its technology, which includes a credit-card-sized electrocardiogram (ECG) device. Initial FDA clearances have been granted, setting the stage for revenue to begin this year. The primary catalyst is sales growth, but there are hurdles to overcome—specifically, convincing heart clinics to adopt the new system and securing FDA approval for expanded use, including home use. Insiders buying shares include several directors and the CFO, who bought in tandem, taking advantage of a public offering instead of buying on the open market. Their actions signal confidence in the outlook, help offset the new dilution, and are echoed by analysts and institutions. The stock has a consensus Moderate Buy rating from the eight analysts who cover HeartBeam, with a 60% buy-side bias and 390% upside at the consensus price target. Even the lowest price target suggests substantial upside, at about 185%, pointing to strong potential. The primary risk is cash burn. The recent offering helped bolster the balance sheet, providing a clear runway through year-end, but it does not eliminate the possibility of a future need for additional capital. Other risks include a slower adoption rate and revenue ramp, regulatory hurdles, and the potential for recall. Factors that may affect adoption include insurance reimbursement rates, which influence end-user profitability. Additional risks include low liquidity in the stock and the potential for violent price swings. 
Sportradar: Insider Buying Meets Short-Seller PressureSportradar’s stock price is oversold and poised to rebound by mid-2026, but the market faces notable risks. The company is under regulatory scrutiny for practices in previous years, and a short-seller report has raised fresh concerns. Short-sellers allege that the business is grounded in black-and-gray sports-betting markets, setting the stage for lost legitimate business and potential license cancellations. Insiders buying stock include several directors and the CEO, who made multiple purchases in Q2. They own approximately 4% of the stock and have significant skin in the game. Their purchases are reinforced by institutions that own more than 50% of the stock and have been aggressively accumulating it. While some institutions have sold, more have bought, leading to a trailing-12-month balance of approximately $1.5 to $1, with activity picking up in Q2. The Q2 activity shows primarily buying, at a pace of more than $10 to $1. Analyst sentiment has contributed to SRAD’s price decline, but the stock has outpaced that trend. As it stands, SRAD stock has a consensus Moderate Buy rating from the 19 analysts who cover it, with a 68% buy-side bias and more than 75% upside to the consensus price target. While the trend points to the low end, most revisions still imply substantial double-digit upside, and the low target sets a price floor that has yet to be broken. 
Granite Ridge: Insiders Buy High YieldGranite Ridge is a non-operated oil exploration and production company with a portfolio of properties in key U.S. production regions. The company partners with proven operators, relying on them to maintain crews and field operations while generating revenue from its share of oil production. Insiders are buying in 2026 to signal confidence in the cash flow, the stock's low valuation, and dividend safety. The dividend is a critical factor, as this stock yields nearly 9%. Insiders who bought include several directors, the CEO, and the CFO. The group collectively owns about 8% of the stock. Institutions are also buying. They own only 30% of the shares, but they provide ample support, buying at a pace of more than $2 to $1. Analysts, however, are less bullish on the stock, with recent downgrades resulting in a consensus Reduce rating. The single analyst who has issued a price target calls for more than 100% upside relative to consensus. The biggest risk is cash flow and cash burn. While the company is well-capitalized and generating healthy cash flow, its aggressive growth strategy is burning cash as costs rise. The risk is to the dividend, which is well above 100% of earnings. Chart price action shows a bottom for this market and the potential for a rebound. The caveat is that a trading range remains in place and upside is limited. The likely outcome is that this market remains below $6 in 2026. 
. |
